BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35178674)

  • 1. Advances in the Treatment of Hairy Cell Leukemia Variant.
    Tran J; Gaulin C; Tallman MS
    Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
    Paillassa J; Maitre E; Troussard X
    Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
    Janus A; Robak T
    Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on the biology and treatment options for hairy cell leukemia.
    Jain P; Pemmaraju N; Ravandi F
    Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I manage patients with hairy cell leukaemia.
    Thompson PA; Ravandi F
    Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
    Paillassa J; Safa F; Troussard X
    Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic options for relapsed hairy cell leukemia.
    Jain P; Polliack A; Ravandi F
    Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
    Robak T; Robak P
    Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
    Nobre CF; Newman MJ; DeLisa A; Newman P
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hairy cell leukemia: present and future directions.
    Kreitman RJ
    Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hairy cell leukemia.
    Chihara D; Kreitman RJ
    Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
    King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
    Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
    [No Abstract]   [Full Text] [Related]  

  • 13. Hairy cell leukemia: a brief update on current knowledge and treatment prospects.
    Puła A; Robak T
    Curr Opin Oncol; 2021 Sep; 33(5):412-419. PubMed ID: 34264896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hairy Cell Leukemia: Where Are We in 2023?
    Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
    Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Troussard X; Maître E; Cornet E
    Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Falini B; De Carolis L; Tiacci E
    Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on hairy cell leukemia.
    Kreitman RJ; Arons E
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoconjugates and new molecular targets in hairy cell leukemia.
    Kreitman RJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
    Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
    J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hairy cell leukemia variant.
    Robak T
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.